DENTSPLY SIRONA (NASDAQ:XRAY) Given New $25.00 Price Target at Needham & Company LLC

DENTSPLY SIRONA (NASDAQ:XRAY - Free Report) had its price objective increased by Needham & Company LLC from $23.00 to $25.00 in a report published on Thursday,Benzinga reports. The firm currently has a buy rating on the medical instruments supplier's stock.

Other analysts also recently issued reports about the stock. Morgan Stanley reduced their target price on shares of DENTSPLY SIRONA from $30.00 to $23.00 and set an "overweight" rating on the stock in a report on Tuesday, December 17th. Leerink Partners downgraded DENTSPLY SIRONA from an "outperform" rating to a "market perform" rating in a research report on Thursday, November 7th. Leerink Partnrs downgraded DENTSPLY SIRONA from a "strong-buy" rating to a "hold" rating in a research report on Thursday, November 7th. Barrington Research decreased their price target on DENTSPLY SIRONA from $36.00 to $24.00 and set an "outperform" rating on the stock in a report on Friday, November 8th. Finally, Jefferies Financial Group lowered shares of DENTSPLY SIRONA from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $30.00 to $20.00 in a research note on Thursday, January 23rd. Ten equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, DENTSPLY SIRONA presently has an average rating of "Hold" and a consensus target price of $26.33.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ XRAY traded down $0.41 during mid-day trading on Thursday, reaching $19.35. The company's stock had a trading volume of 1,831,373 shares, compared to its average volume of 2,405,522. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.25 and a quick ratio of 0.84. DENTSPLY SIRONA has a 52 week low of $17.21 and a 52 week high of $34.91. The stock has a fifty day moving average of $19.14 and a two-hundred day moving average of $22.38. The firm has a market capitalization of $3.85 billion, a PE ratio of -9.35, a P/E/G ratio of 1.88 and a beta of 0.96.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.02. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. The company had revenue of $951.00 million for the quarter, compared to the consensus estimate of $939.10 million. During the same period in the previous year, the business earned $0.49 earnings per share. The firm's revenue for the quarter was up .4% on a year-over-year basis. As a group, sell-side analysts anticipate that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 10th. Stockholders of record on Friday, December 27th were paid a $0.16 dividend. The ex-dividend date was Friday, December 27th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 3.31%. DENTSPLY SIRONA's dividend payout ratio (DPR) is currently -30.92%.

Institutional Trading of DENTSPLY SIRONA

Several large investors have recently bought and sold shares of the company. Pacer Advisors Inc. boosted its stake in shares of DENTSPLY SIRONA by 15,105.1% in the fourth quarter. Pacer Advisors Inc. now owns 4,503,591 shares of the medical instruments supplier's stock valued at $85,478,000 after purchasing an additional 4,473,972 shares during the period. JPMorgan Chase & Co. grew its stake in shares of DENTSPLY SIRONA by 206.3% during the third quarter. JPMorgan Chase & Co. now owns 1,847,389 shares of the medical instruments supplier's stock valued at $49,990,000 after acquiring an additional 1,244,326 shares in the last quarter. Invenomic Capital Management LP purchased a new stake in shares of DENTSPLY SIRONA during the third quarter worth about $23,724,000. National Bank of Canada FI lifted its stake in shares of DENTSPLY SIRONA by 85.8% in the third quarter. National Bank of Canada FI now owns 1,628,200 shares of the medical instruments supplier's stock worth $44,059,000 after acquiring an additional 751,800 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in DENTSPLY SIRONA by 50.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,065,773 shares of the medical instruments supplier's stock valued at $55,900,000 after purchasing an additional 692,100 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company's stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.